Exelixis, Inc. company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo.

The Government Pharmaceutical Organization (GPO) provides the medicine that keeps Thai residents healthy. The organization researches and manufactures a wide variety of pharmaceutical products for ailments involving the respiratory, cardiovascular, and gastrointestinal systems, and vaccines, among others. GPO also makes vitamins, supplements, and diagnostic test kits. The organization's more than hundreds of pharmacists offer services through its about a dozen facilities, including retail drug stores. The Government Pharmaceutical Laboratories and the Division of Medical Depot merged to form GPO in 1966. The organization is part of Thailand's Ministry of Public Health.

Axcan Pharma Inc. company develops and sells drugs mainly to treat gastrointestinal ailments. Its Urso line treats chronic liver disease, while two of its products (Canasa and Salofalk) offer relief for inflammatory bowel diseases. Axcan's Ultrase and Viokase are digestive aids for patients with exocrine pancreatic insufficiency, a condition associated with cystic fibrosis. The firm also owns the global rights to Photofrin, a photodynamic drug developed by QLT with applications for esophageal, gastric, and lung cancers. Other products include ulcer and diarrhea treatments, as well as chewable multivitamins. Axcan was acquired by TPG Capital for $1.3 billion in early 2008.

Nature's Way Holding Company manufactures and markets nutritional supplements and other OTC products which are sold with the Enzymatic Therapy, Nature's Way, and Remifemin labels through natural foods retailers and mass market retailers in the US. Its products are aimed to alleviate everything from sleeplessness to hot flashes and are distributed throughout the US and to more than 40 other countries. Its Integrative Therapeutics and Vitaline brands are sold through healthcare practitioners' offices. The company is a unit of German firm Dr. Willmar Schwabe Pharmaceuticals.

Novartis AG company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division engages in the research, development, manufacture, distribution, and sale of pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; and immunology and infectious diseases. Novartis company's Vaccines and Diagnostics division offers preventive vaccines and diagnostic tools. This division provides influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; anti-infectives; protein or biotechnology-based products; and cytotoxic products, as well as offers biotech manufacturing services to other companies on a contract basis. Novartis company's Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC offers readily available consumer medicines. Animal Health provides veterinary products for farm and companion animals. CIBA Vision manufactures contact lenses and lens care products. Novartis AG has a strategic alliance with Intercell AG to develop vaccines; and a strategic partnership with Lonza, a Swiss pharmaceuticals manufacturing company.

CardioVascular BioTherapeutics, Inc. (Cardio) is a development-stage biopharmaceutical company focused on developing drugs to stimulate the growth of new blood vessels for the treatment of cardiovascular diseases. The active pharmaceutical ingredient (API) in the Company’s drug candidates is acidic human fibroblast growth factor-1, FGF-1141 (formerly called Cardio Vascu-Grow) and it facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. This process is referred to as angiogenesis in the scientific community. The Company’s research and development is focused on developing new drug candidates, in which FGF-1141 is the API for the treatment of cardiovascular diseases, where the growth of new blood vessels can improve the outcome for patients. The Company conducts research to identify and evaluate medical indications that may benefit from its drug candidates.

Otsuka Pharmaceutical Co. (OPC) is a manufacturer and distributor of pharmaceuticals, clinical testing and medical equipment, and food products. The company operates six business segments specializing in branded prescriptions, over-the-counter drugs, clinical nutritionals, diagnostic substances and devices, nutraceuticals, and skin care products ("cosmedics"). OPC's medicinal products include Mikelan eye drops for glaucoma treatment and Pletaal anti-platelet treatment. The company's line of nutraceutical consumer health products include FIBE-MINI dietary fiber supplement, Calorie Mate foods, and Pocari Sweat sports drink. Otsuka Pharmaceutical is part of the very diverse Otsuka Group.

The Italian subsidiary of Swiss drug maker Roche manufactures all of the company's most successful medications -- hepatitis B and C drug Pegasys, cancer drugs Herceptin and Avastin, and MabThera, for non-Hodgkin lymphoma. Roche S.p.A.'s business is roughly 40% oncology and hematology, 30% specialty care (Pegasys, Neorecormon, Copegus), and 30% primary care (analgesics, antibiotics). Its 700,000-square-foot production facility in Segrate, a town near Milan in northern Italy, produces almost 1,400 tons of medication every year, about 60% of which is exported across Europe.

Expression Analysis isn't run by body language specialists, but when researchers need DNA analyzed, they can turn to Expression Analysis. The company provides outsourced microarray processing, genotyping, RNA amplification and isolation, and other data generation and analysis services. The company uses gene research platforms developed by companies including Affymetrix, Life Technologies, and Illumina. It analyzes a variety of samples including whole blood, tissue cells, and frozen samples, for customers including government agencies and pharmaceutical development firms.

GlaxoSmithKline Argentina has manufacturing and supply operations, as well as units devoted to consumer healthcare (dermatological, analgesic, oral care, gastrointestinal relief, and vitamin products) and to pharmaceutical products (anesthetic, antibiotic, oncologic, respiratory, and other drugs, as well as vaccines). A unit of GlaxoSmithKline, GSK Argentina also conducts research and pharmaceutical trials for its parent. Areas of focus include rheumatoid arthritis, epilepsy, diabetes, oncology, and Alzheimer's. The company's manufacturing and supply operations operate a production facility and export GSK goods to other parts of Central America.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.